The combination of lenvatinib and pembrolizumab improved progression-free survival (PFS) and overall survival (OS) compared with physician’s choice of treatment (TPC) among patients with advanced endometrial cancer with prior exposure to platinum-based therapy, regardless of DNA mismatch repair (MMR) status, according to results of a phase III study presented at IGCS 2021.
Intensive follow-up for 5 years did not improve overall survival (OS) or relapse-free survival (RFS) in patients who have undergone surgical treatment for endometrial cancer, according to results of the TOTEM study presented at IGCS 2021.
New drug applications approved by US FDA as of 16-31 August 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Hormonal therapy with a levonorgestrel-releasing intrauterine device (LNG-IUD) led to a high pathological complete response (pCR) rate in women with early-stage endometrial cancer, according to the feMMe trial presented at SGO 2021 Meeting.
In patients with advanced endometrial cancer with prior platinum chemotherapy exposure, a combination of lenvatinib + pembrolizumab improved survival compared with physician’s choice of treatment (TPC), results of the phase III Study 309/KEYNOTE-775 trial showed.
The addition of radiation therapy to chemotherapy does not provide a relapse-free survival (RFS) advantage over chemotherapy only in stage III or IVA endometrial cancer, according to the phase III GOG 258* trial.
Use of tamoxifen does not appear to increase the risk of endometrial cancer in women with endometrial polyps, a study has found. Risk factors include abnormal uterine bleeding, older age and nulliparous status.
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Thalassaemia becomes a global health problem. Most women with thalassaemia trait can be picked up by universal prenatal screening for thalassaemia using mean corpuscular volume/haemoglobin, followed by haemoglobin pattern with or without DNA analysis.